United States

People: Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

13 Dec 2018
Change (% chg)

$-0.37 (-1.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pehl, Michael 

Mr. Michael F. Pehl has been appointed President, Chief Executive Officer, Director of the Company. He is our President and Chief Executive Officer, has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Previously, Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --